Dunhill Financial’s Supernus Pharmaceuticals SUPN Stock Holding History

Dunhill Financial’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$60	Hold	1	–	–	﹤0.01%	1562
2025 Q4	$58	Buy	+1	New	+$49	﹤0.01%	1608

Other funds holding SUPN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dunhill Financial's SUPN Position: Q1 2026 in Review

Dunhill Financial held its Supernus Pharmaceuticals (SUPN) position steady in Q1 2026 at 1 share worth $60. The position accounts for ﹤0.01% of the portfolio, ranked #1562.

Dunhill Financial first reported a position in SUPN in Q4 2025 and has held it in 2 quarters since. 327 funds tracked by Wall St. Rank hold SUPN as of Q1 2026.

Dunhill Financial held 1 share of Supernus Pharmaceuticals worth $60 as of Q1 2026.
Dunhill Financial left its Supernus Pharmaceuticals share count unchanged in Q1 2026.
Supernus Pharmaceuticals made up ﹤0.01% of Dunhill Financial's portfolio in Q1 2026, its #1562 holding.
Dunhill Financial first reported a position in Supernus Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
327 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2026.

Based on Dunhill Financial's 13F filing for Q1 2026, filed 6 May 2026.